Mirum Pharmaceuticals, Inc.

NasdaqGM MIRM

Mirum Pharmaceuticals, Inc. Price to Book Ratio (P/B) on January 14, 2025: 8.81

Mirum Pharmaceuticals, Inc. Price to Book Ratio (P/B) is 8.81 on January 14, 2025, a -71.57% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Mirum Pharmaceuticals, Inc. 52-week high Price to Book Ratio (P/B) is 34.71 on February 12, 2024, which is 294.01% above the current Price to Book Ratio (P/B).
Mirum Pharmaceuticals, Inc. 52-week low Price to Book Ratio (P/B) is 6.47 on July 02, 2024, which is -26.53% below the current Price to Book Ratio (P/B).
Mirum Pharmaceuticals, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 15.82.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGM: MIRM

Mirum Pharmaceuticals, Inc.

CEO	Mr. Christopher Peetz
IPO Date	July 18, 2019
Location	United States
Headquarters	950 Tower Lane
Employees	311
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Key trends

Past 5 years